Stacie Calad-Thomson
Stacie, a former pharma and biotech leader, recently joined NVIDIA to further enable AI adoption across healthcare and the life sciences. She also serves as the vice chair of the Alliance for Artificial Intelligence in Healthcare (AAIH). In her 13+ years at GSK, she led R&D initiatives and co-founded the ATOM consortium. More recently, she held leadership roles at AI drug discovery startups Atomwise, where she was a VP of Partnerships, and BioSymetrics, where she was the Chief Strategy Officer. Stacie holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from UC Irvine.
NVIDIA
Reprogramming Biology at Cloud Speed
-
Biotech is accelerating—and cloud infrastructure is the catalyst. This session explores how scalable compute, AI-native architectures, and real-time data integration are transforming the way biology is engineered. From protein design to genome editing, discover how innovators are leveraging cloud-native platforms to run complex simulations, automate workflows, and shorten the cycle from hypothesis to insight. Hear from leaders building the tools that are making biology programmable, iterative, and as fast as software development.
AI-Driven Insights: Predicting Efficacy and Toxicity in Next-Gen Drug Discovery
-
AI is revolutionizing drug discovery—not just by accelerating timelines, but by enhancing our ability to predict how drugs behave in the body. This session highlights cutting-edge approaches like dynamic systems simulations that model mechanistic interactions at the cellular level. Learn how platforms are able to generating causal hypotheses to forecast both efficacy and toxicity, unlocking smarter, safer therapeutic development.
